SA4503, a novel cognitive enhancer, with σ1 receptor agonistic properties

Behavioural Brain Research

Volumn 83, Issue 1-2, 1997, Pages 221-224

  Matsuno, Kiyoshi ^a   Senda, Toshihiko ^a   Kobayashi, Tetsuya ^a   Okamoto, Kazuyoshi ^a   Nakata, Katsuhiko ^a   Mita, Shiro ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

acetylcholine; agonistic activity; catalepsy; cognitive enhancer; regional difference; SA4503; tetrahydroaminoacridine; 1 receptor subtype

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; HALOPERIDOL; NOOTROPIC AGENT; RECEPTOR SUBTYPE; SCOPOLAMINE; TACRINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CATALEPSY; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0031081048     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(97)86074-3     Document Type: Conference Paper

References (14)

1. [1] Bartholini, G., Stadler, H. and Lloyd, K.G., Cholinergic-dopaminergic interregulations within the extrapyramidal systems, In P.G. Waser (Ed), Cholinergic mechanisms, Raven Press, New York, 1975, pp. 411-418.
2. [2] Coyle, J.T., Price, D.L. and Delong, M.R., Alzheimer's disease: A disorder of cortical innervation, Science, 219 (1983) 1184-1189.
3. [3] Ferris, C.D., Hirsch, D.J., Brooks, B.P. and Snyder, S.H., σ Receptors: from molecule to man, J. Neurochem., 57 (1991) 729-737.
4. [4] Itzhak, Y., Multiple sigma binding sites in the brain. In Y. Itzhak (Ed.), Sigma Receptors, Academic Press Inc., San Diego, 1994, pp. 113-137.
5. [5] Matsuno, K., Matsunaga, K. and Mita, S., Increase of extracellular acetylcholine level in rat frontal cortex induced by (+)-N-allylnormetazocine as measured by brain microdialysis, Brain Res., 575 (1992) 315-319.
6. [6] Matsuno, K., Matsunaga, K., Senda, T. and Mita, S., Increase in extracellular acetylcholine level by sigma ligands in rat frontal cortex, J. Pharmacol. Exp. Ther., 265 (1993) 851-859.
7. 2 antagonists on drug-induced impairment of passive avoidance response in mice: comparison with acetylcholinesterase inhibitors, Psychopharmacology, 112 (1993) 134-141.
8. [8] Matsuno, K., Senda, T., Matsunaga, K. and Mita, S., Ameliorating effects of σ receptor ligands on the impairment of passive avoidance tasks in mice: involvement in the central acetylcholinergic system, Eur. J. Pharmacol., 261 (1994) 43-51.
9. 1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats, Brain Res., 690 (1995) 200-206.
10. [10] Mesulam, M.-M., Mufson, E.J., Wainer, B.H. and Levey, A.I, Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1-Ch6), Neuroscience, 10 (1983) 1185-1201.
11. [11] Ott, B.R. and Lannon, M.C., Exacerbation of parkinsonism by tacrine, Clin. Neuropharmacol., 15 (1992) 322-325.
12. [12] Quirion, R., Bowen, W.D., Itzhak, Y., Junien, J.L., Musacchio, J.M., Rothman, R.B., Su, T-P., Tam, S.W. and Taylor, D.P., A proposal for the classification of sigma binding sites, Trends Pharmacol. Sci., 13 (1992) 85-86.
13. [13] Su, T-P., σ Receptors, putative links between nervous, endocrine and immune systems, Eur. J. Biochem., 200 (1991) 633-642.
14. 2, In T. Kameyama, T. Nabeshima and E.F. Domino (Eds.), NMDA Receptor Related Agents: Biochemistry, Pharmacology and Behavior, NPP Books, Ann Arbor, 1991, pp. 227-233.